Skip to main content Accessibility help
×
Home

Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies

  • Richard Camicioli (a1) and Nancy Fisher (a2)

Abstract

Dementia occurs in up to 30% of people with Parkinson's disease and is a major cause of disability. Pathologically, Parkinson's dementia, where dementia follows the onset of parkinsonism by at least one year, overlaps with dementia with Lewy bodies. We review the functional impact, definitions, neuropsychology, epidemiology and pathophysiology of Parkinson's dementia, dementia with Lewy bodies and their overlap. Associated psychiatric and imaging findings are also considered. Lastly, current and emerging approaches to assessment and treatment in patients with these Lewy body associated dementias are presented.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies
      Available formats
      ×

Copyright

References

Hide All
1.Kis, B, Schrag, A, Ben-Shlomo, Y, et al. Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology 2002; 58:18201825.
2.Chen, RC, Chang, SF, Su, CL, et al. Prevalence, incidence, andmortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001; 57:16791686.
3.de Rijk, MC, Launer, LJ, Berger, K, et al. Prevalence of Parkinson’sdisease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54:S21-S23.
4.Mayeux, R, Denaro, J, Hemenegildo, N, et al. A population-basedinvestigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49:492497.
5.Murman, DL, Chen, Q, Colucci, PM, et al. Comparison of healthcareutilization and direct costs in three degenerative dementias. Am J Geriatr Psychiatry 2002; 10:328336.
6.Parashos, SA, Maraganore, DM, O’Brien, PC, Rocca, WA.Medicalservices utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002; 77:918925.
7.Goedert, M.Parkinson’s disease and other alpha-synucleinopathies. Clin Chem Lab Med 2001; 39:308312.
8.Gelb, DJ, Oliver, E, Gilman, S.Diagnostic criteria for Parkinsondisease. Arch Neurol 1999; 56:3339.
9.Hughes, AJ, Daniel, SE, Lees, AJ.Improved accuracy of clinicaldiagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57:14971499.
10.Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ.The accuracy ofdiagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861870.
11.Meara, J, Bhowmick, BK, Hobson, P.Accuracy of diagnosis inpatients with presumed Parkinson’s disease. Age Ageing 1999; 28:99102.
12.American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000.
13.Knopman, DS, DeKosky, ST, Cummings, JL, et al. Practiceparameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:11431153.
14.Snow, B, Wiens, M, Hertzman, C, Calne, D.A community survey ofParkinson’s disease. CMAJ 1989; 141:418422.
15.Ebmeier, KP, Calder, SA, Crawford, JR, et al. Dementia in idiopathicParkinson’s disease: prevalence and relationship with symptoms and signs of parkinsonism. Psychol Med 1991; 21:6976.
16.Ebmeier, KP, Calder, SA, Crawford, JR, et al. Clinical featurespredicting dementia in idiopathic Parkinson’s disease: a follow-up study. Neurology 1990; 40:12221224.
17.Tison, F, Dartigues, JF, Auriacombe, S, et al. Dementia in Parkinson’sdisease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45:705708.
18.Wang, SJ, Fuh, JL, Teng, EL, et al. A door-to-door survey ofParkinson’s disease in a Chinese population in Kinmen. Arch Neurol 1996; 53:6671.
19.Aarsland, D, Tandberg, E, Larsen, JP, Cummings, JL.Frequency ofdementia in Parkinson disease. Arch Neurol 1996; 53:538542.
20.Bower, JH, Maraganore, DM, McDonnell, SK, Rocca, WA.Incidenceand distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 1999; 52:12141220.
21.Palazzini, E, Soliveri, P, Filippini, G, et al. Progression of motor andcognitive impairment in Parkinson’s disease. J Neurol 1995; 242:535540.
22.Reid, WGJ, Hely, MA, Morris, JGL, et al. A longitudinal study ofParkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neuroscience 1996; 3:327333.
23.Mahieux, F, Fenelon, G, Flahault, A, et al. Neuropsychological prediction of dementia in Parkinson’s disease. J NeurolNeurosurg Psychiatry 1998; 64:178183.
24.Hughes, TA, Ross, HF, Musa, S, et al. A 10-year study of theincidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000; 54:15961602.
25.Levy, G, Tang, MX, Cote, LJ, et al. Motor impairment in PD:relationship to incident dementia and age. Neurology 2000; 55:539544.
26.Aarsland, D, Andersen, K, Larsen, JP, et al. Risk of dementia inParkinson’s disease: a community-based, prospective study. Neurology 2001; 56:730736.
27.Rajput, AH.Prevalence of dementia in Parkinson’s disease. In: Huber, SJ, Cummings, JL, (Eds). Parkinson’s Disease: Neuro-behavioral Aspects. New York: Oxford University Press, 1992:119131.
28.Stevens, T, Livingston, G, Kitchen, G, et al. Islington study ofdementia subtypes in the community. Br J Psychiatry 2002; 180:270276.
29.McKeith, IG, Ballard, CG, Perry, RH, et al. Prospective validation ofconsensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54:10501058.
30.Marinus, J, Ramaker, C, van Hilten, JJ, Stiggelbout, AM.Healthrelated quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002; 72:241248.
31.Schrag, A, Jahanshahi, M, Quinn, N.What contributes to quality oflife in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000; 69:308312.
32.Dymek, MP, Atchison, P, Harrell, L, Marson, DC.Competency toconsent to medical treatment in cognitively impaired patients with Parkinson’s disease. Neurology 2001; 56:1724.
33.Rockwood, K, Stolee, P, McDowell, I.Factors associated withinstitutionalization of older people in Canada: testing a multifactorial definition of frailty. J Am Geriatr Soc 1996; 44:578582.
34.Aarsland, D, Larsen, JP,Tandberg, E, Laake, K.Predictors of nursinghome placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48:938942.
35.Goetz, CG, Stebbins, GT.Risk factors for nursing home placementin advanced Parkinson’s disease. Neurology 1993; 43:22272229.
36.Morgante, L, Salemi, G, Meneghini, F, et al. Parkinson diseasesurvival: a population-based study. Arch Neurol 2000; 57:507512.
37.Bennett, DA, Beckett, LA, Murray, AM, et al. Prevalence ofparkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334:7176.
38.Berger, K, Breteler, MM, Helmer, C, et al. Prognosis withParkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54:S24-S27.
39.Mitchell, SL, Rockwood, K.The association between parkinsonism, Alzheimer’s disease, and mortality: a comprehensive approach. J Am Geriatr Soc 2000; 48:422425.
40.Louis, ED, Marder, K, Cote, L, Tang, M, Mayeux, R.Mortality fromParkinson disease. Arch Neurol 1997; 54:260264.
41.Fernandez, HH, Lapane, KL.Predictors of mortality among nursinghome residents with a diagnosis of Parkinson’s disease. Med Sci Monit 2002; 8:CR241-246.
42.Cummings, JL, Benson, DF.Dementia: A Clinical Approach. Boston: Butterworth-Heinemann, 1992.
43.U.S. Department of Health and Human Services. The internationalclassification of diseases 9th Revision – Clinical Modification (ICD-9-CM). Vol. 1, 1980.
44.World Health Organization. The ICD-10 classification of mentaland behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
45.American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III. Washington, D.C.: American Psychiatric Association, 1982.
46.American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders: DSM-III-R. Washington, DC: American Psychiatric Association, 1987.
47.American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994.
48.McKhann, G, Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34:939944.
49.McKeith, IG, Galasko, D, Kosaka, K, et al. Consensus guidelines forthe clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:11131124.
50.Cummings, JL, Benson, DF.Subcortical dementia. Review of anemerging concept. Arch Neurol 1984; 41:874879.
51.Cummings, JL.Introduction. In: Cummings, JL, (Ed). Subcortical dementia. New York: Oxford, 1990:316.
52.La Rue, A.Aging and neuropsychological assessment. Criticalissues in neuropsychology. New York: Plenum Press, 1992.
53.Huber, SJ, Shuttleworth, EC, Paulson, GW, Bellchambers, MJ, Clapp, LE. Cortical vs subcortical dementia. Neuropsychological differences. Arch Neurol 1986; 43:392394.
54.Tierney, MC, Nores, A, Snow, WG, et al. Use of the rey auditory verbal learning test in differentiating normal aging from Alzheimer’s and Parkinson’s Dementia. Psychol Assess 1994; 6:129134.
55.Whitehouse, PJ.The concept of subcortical and cortical dementia: another look. Ann Neurol 1986; 19:16.
56.Hakim, AM, Mathieson, G.Dementia in Parkinson disease: aneuropathologic study. Neurology 1979; 29:12091214.
57.Alvord, EC.The pathology of Parkinsonism. In: Minckler, J, (Ed). Pathology of the Nervous System. New York: McGraw-Hill, 1968:11521161.
58.Harding, AJ, Halliday, GM.Cortical Lewy body pathology in thediagnosis of dementia. Acta Neuropathol (Berl) 2001; 102:355363.
59.Mann, DM, Esiri, MM.The site of the earliest lesions of Alzheimer’sdisease. N Engl J Med 1988; 318:789790.
60.Bondareff, W, Mountjoy, CQ, Roth, M, et al. Age and histopathologicheterogeneity in Alzheimer’s disease. Evidence for subtypes. Arch Gen Psychiatry 1987; 44:412417.
61.Benke, T.The neuropsychological assessment of dementia. CNSSpectrum 2002; 7:371375.
62.Mattis, S.Dementia Rating Scale: Professional manual. Odessa, Florida: Psychological Assessment Resources, 1998.
63.Folstein, MF, Folstein, SE, McHugh, PR.“Mini-mental state”. Apractical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189198.
64.Spreen, O, Strauss, E.A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York: Oxford University Press, 1998.
65.McFadden, L, Mohr, E, Sampson, M, Mendis, T, Grimes, JD.A profileanalysis of demented and nondemented Parkinson’s disease patients. Adv Neurol 1996; 69:339341.
66.Graham, JM, Sagar, HJ.A data-driven approach to the study ofheterogeneity in idiopathic Parkinson’s disease: identification of three distinct subtypes. Mov Disord 1999; 14:1020.
67.Dujardin, K, Defebvre, L, Grunberg, C, Becquet, E, Destee, A.Memory and executive function in sporadic and familial Parkinson’s disease. Brain 2001; 124:389398.
68.Green, J, McDonald, WM, Vitek, JL, et al. Cognitive impairments inadvanced PD without dementia. Neurology 2002; 59:13201324.
69.Whittington, CJ, Podd, J, Kan, MM.Recognition memory impairment in Parkinson’s disease: power and meta-analyses. Neuropsychology 2000; 14:233246.
70.Goldman, WP, Baty, JD, Buckles, VD, Sahrmann, S, Morris, JC. Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia. Arch Neurol 1998; 55:674680.
71.Hoppe, CD, Muller, UD, Werheid, KD, Thone, AD, von Cramon, YD.Digit Ordering Test: clinical, psychometric, and experimental evaluation of a verbal working memory test. Clin Neuropsychol 2000; 14:3855.
72.Zakzanis, KK, Freedman, M.A neuropsychological comparison ofdemented and nondemented patients with Parkinson’s disease. Appl Neuropsychol 1999; 6:129146.
73.Levin, BE, Llabre, MM, Weiner, WJ.Cognitive impairmentsassociated with early Parkinson’s disease. Neurology 1989; 39:557561.
74.Huber, SJ, Freidenberg, DL, Shuttleworth, EC, Paulson, GW, Christy, JA.Neuropsychological impairments associated with severity of Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1989; 1:154158.
75.Bublak, P, Muller, U, Gron, G, Reuter, M, von Cramon, DY. Manipulation of working memory information is impaired in Parkinson’s disease and related to working memory capacity. Neuropsychology 2002; 16:577590.
76.Peavy, GM, Salmon, D, Bear, PI, et al. Detection of mild cognitivedeficits in Parkinson’s disease patients with the WAIS-R NI. J Int Neuropsychol Soc 2001; 7:535543.
77.Cooper, JA, Sagar, HJ, Jordan, N, Harvey, NS, Sullivan, EV.Cognitiveimpairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain 1991; 114 (Pt 5):20952122.
78.Taylor, AE, Saint-Cyr, JA, Lang, AE.Frontal lobe dysfunction inParkinson’s disease. The cortical focus of neostriatal out flow. Brain 1986; 109 (Pt 5):845883.
79.Breen, EK.Recall and recognition memory in Parkinson’s disease. Cortex 1993; 29:91102.
80.Ivory, SJ, Knight, RG, Longmore, BE, Caradoc-Davies, T.Verbalmemory in nondemented patients with idiopathic Parkinson’s disease. Neuropsychologia 1999; 37:817828.
81.Pate, DS, Margolin, DI.Cognitive slowing in Parkinson’s and Alzheimer’s patients: distinguishing bradyphrenia from dementia. Neurology 1994; 44:669674.
82.Grossman, M, Zurif, E, Lee, C, et al. Information processing speedand sentence comprehension in Parkinson’s disease. Neuropsychology 2002; 16:174181.
83.Piatt, AL, Fields, JA, Paolo, AM, Koller, WC, Troster, AI.Lexical, semantic, and action verbal fluency in Parkinson’s disease with andwithout dementia. J Clin Exp Neuropsychol 1999; 21:435443.
84.McPherson, S, Cummings, J.Neuropsychological aspects of Parkinson’s disease and Parkinsonism. In: Grant, I, Adams, K, (Eds). Neuropsychological Assessment of NeuropsychiatricDisorders, 1996:288311.
85.Katsarou, Z, Bostantiopoulou, S, Alevriadou, A, et al. A longitudinal study of visuospatial discrimination in parkinsonian patients. Percept Mot Skills 1998; 86:171180.
86.Richards, M, Cote, LJ, Stern, Y.Executive function in Parkinson’sdisease: set-shifting or set-maintenance? J Clin ExpNeuropsychol 1993; 15:266279.
87.Summerfield, C, Gomez-Anson, B, Tolosa, E, et al. Dementia inParkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol 2002; 59:14151420.
88.Mortimer, JA, Pirozzolo, FJ, Hansch, EJ, Webster, DD.Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology 1982; 32:133137.
89.Pillon, B, Dubois, B, Lhermitte, F, Agid, Y.Heterogeneity of cognitiveimpairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986; 36:11791185.
90.Ross, HF, Hughes, TA, Boyd, JL, et al. The evolution and profile ofdementia in Parkinson’s disease. Adv Neurol 1996; 69:343347.
91.Hansen, L, Salmon, D, Galasko, D, et al. The Lewy body variant ofAlzheimer’s disease: a clinical and pathologic entity. Neurology 1990; 40:18.
92.Calderon, J, Perry, RJ, Erzinclioglu, SW, et al. Perception, attention,and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001; 70:157164.
93.Lambon, RMA, Powell, J, Howard, D, et al. Semantic memory isimpaired in both dementia with Lewy bodies and dementia of Alzheimer’s type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry 2001; 70:149156.
94.Salmon, DP, Galasko, D, Hansen, LA, et al. Neuropsychologicaldeficits associated with diffuse Lewy body disease. Brain Cogn 1996; 31:148165.
95.Galasko, D, Katzman, R, Salmon, DP, Hansen, L.Clinical andneuropathological findings in Lewy body dementias. Brain Cogn 1996; 31:166175.
96.Mori, E, Shimomura, T, Fujimori, M, et al. Visuoperceptualimpairment in dementia with Lewy bodies. Arch Neurol 2000; 57:489493.
97.Salmon, D, Galasko, D.Neuropsychological aspects of Lewy bodydementia. In: Perry, R, McKeith, I, Perry, E, (Eds). Dementia with Lewy Bodies. New York: Cambridge, 1996:99114.
98.Shimomura, T, Mori, E, Yamashita, H, et al. Cognitive loss indementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998; 55:15471552.
99.Simard, M, van Reekum, R, Cohen, T.A review of the cognitive andbehavioralsymptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000; 12:425450.
100.Walker, Z, Allan, RL, Shergill, S, Katona, CL.Neuropsychological performance in Lewy body dementia and Alzheimer’s disease. Br J Psychiatry 1997; 170:156158.
101.Gnanalingham, KK, Byrne, EJ, Thornton, A, Sambrook, MA, Bannister, P.Motor and cognitive function in Lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 1997; 62:243252.
102.Monsch, AU, Bondi, MW, Butters, N, et al. Acomparison of categoryand letter fluency in Alzheimer’s disease and Huntington’s disease. Neuropsychology 1994; 8:2530.
103.Walker, MP, Ayre, GA, Cummings, JL, et al. Quantifying fluctuationin dementia with Lewy bodies, Alzheimer’s disease, and vasculardementia. Neurology 2000; 54:16161625.
104.Sahgal, A, Galloway, PH, McKeith, IG.A comparative study ofattentional deficits in senile dementias of Alzheimer and Lewybody types. Dementia 1992; 3:350354.
105.Ballard, C, O’Brien, J, Gray, A, et al. Attention and fluctuatingattention in patients with dementia with Lewy bodies andAlzheimer disease. Arch Neurol 2001; 58:977982.
106.McKeith, IG.Dementia with Lewy bodies: clinical and pathologicaldiagnosis. Alzheimer Reports 1998; 1:8387.
107.Doubleday, EK, Snowden, JS, Varma, AR, Neary, D.Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer ’s disease. J Neurol Neurosurg Psychiatry 2002; 72:602607.
108.Walker, MP, Ayre, GA, Cummings, JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusionin dementia. Br J Psychiatry 2000; 177:252256.
109.Ballard, CG, Aarsland, D, McKeith, I, et al. Fluctuations in attention:PD dementia vs DLB with parkinsonism. Neurology 2002; 59:17141720.
110.Connor, DJ, Salmon, DP, Sandy, TJ, et al. Cognitive profiles ofautopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998; 55:9941000.
111.Marder, K, Leung, D, Tang, M, et al. Are demented patients withParkinson’s disease accurately reflected in prevalence surveys? A survival analysis. Neurology 1991; 41:12401243.
112.Levin, BE, Katzen, HL, Klein, B, Llabre, ML.Cognitive declineaffects subject attrition in longitudinal research. J Clin Exp Neuropsychol 2000; 22:580586.
113.Glatt, SL, Hubble, JP, Lyons, K, et al. Risk factors for dementia inParkinson’s disease: effect of education. Neuroepidemiology 1996; 15:2025.
114.Jacobs, DM, Marder, K, Cote, LJ, et al. Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995; 45:16911696.
115.Levy, G, Jacobs, DM, Tang, MX, et al. Memory and executivefunction impairment predict dementia in Parkinson’s disease. Mov Disord 2002; 17:12211226.
116.Levy, G, Tang, MX, Cote, LJ, et al. Do risk factors for Alzheimer’sdisease predict dementia in Parkinson’s disease? An exploratory study. Mov Disord 2002; 17:250257.
117.Fernandez, HH, Lapane, KL.Estrogen use among nursing homeresidents with a diagnosis of Parkinson’s disease. Mov Disord 2000; 15:11191124.
118.Marder, K, Tang, MX, Alfaro, B, et al. Post menopausal estrogen useand Parkinson’s disease with and without dementia. Neurology 1998; 50:11411143.
119.Marder, K, Tang, MX, Alfaro, B, et al. Risk of Alzheimer’s disease inrelatives of Parkinson’s disease patients with and without dementia. Neurology 1999; 52:719724.
120.Hofman, A, Schulte, W, Tanja, TA, et al. History of dementia andParkinson’s disease in 1st-degree relatives of patients with Alzheimer’s disease. Neurology 1989; 39:15891592.
121.Parsian, A, Racette, B, Goldsmith, LJ, Perlmutter, JS. Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002; 79:458461.
122.Koller, WC, Glatt, SL, Hubble, JP, et al. Apolipoprotein E genotypesin Parkinson’s disease with and without dementia. Ann Neurol 1995; 37:242245.
123.Inzelberg, R, Chapman, J, Treves, TA, et al. Apolipoprotein e4 inParkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 1998; 12:4548.
124.Harhangi, BS, de Rijk, MC, van Duijn, CM, et al. APOE and the riskof PD with or without dementia in a population-based study. Neurology 2000; 54:12721276.
125.Wakabayashi, K, Kakita, A, Hayashi, S, et al. Apolipoprotein Eepsilon 4 allele and progression of cortical Lewy body pathology in Parkinson’s disease. Acta Neuropathol (Berl) 1998; 95:450454.
126.Mattila, PM, Koskela, T, Roytta, M, et al. Apolipoprotein E epsilon4allele frequency is increased in Parkinson’s disease only with co¬existing Alzheimer pathology. Acta Neuropathol (Berl) 1998; 96:417420.
127.Egensperger, R, Bancher, C, Kosel, S, et al. The apolipoprotein Eepsilon 4 allele in Parkinson’s disease with Alzheimer lesions. Biochem Biophys Res Commun 1996; 224:484486.
128.Li, YJ, Scott, WK, Hedges, DJ, et al. Age at onset in two commonneurodegenerative diseases is genetically controlled. Am J HumGenet 2002; 70:985993.
129.Zareparsi, S, Camicioli, R, Sexton, G, et al. Age at onset of Parkinsondisease and apolipoprotein E genotypes. Am J Med Genet 2002; 107:156161.
130.Mattila, KM, Rinne, JO,Roytta, M, et al. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer’s disease and in Parkinson’s disease with coexisting Alzheimer pathology. J Med Genet 2000; 37:766770.
131.Mattila, KM, Rinne, JO, Roytta, M, Laippala, P, Lehtimaki, T.Lack ofassociation between an estrogen receptor 1 gene polymorphism and Parkinson’s disease with dementia. Acta Neurol Scand 2002; 106:128130.
132.Isoe-Wada, K, Maeda, M, Yong, J, et al. Positive association betweenan estrogen receptor gene polymorphism and Parkinson’s disease with dementia. Eur J Neurol 1999; 6:431435.
133.Egensperger, R, Kosel, S, Schnopp, NM, Mehraein, P, Graeber, MB.Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer’s and Parkinson’s diseases. Neuropathol Appl Neurobiol 1997; 23:315321.
134.Tsuang, DW, Dalan, AM, Eugenio, CJ, et al. Familial dementia withLewy bodies: a clinical and neuropathological study of 2 families. Arch Neurol 2002; 59:16221630.
135.Galvin, JE, Lee, SL, Perry, A, et al. Familial dementia with Lewybodies: clinicopathologic analysis of two kindreds. Neurology 2002; 59:10791082.
136.Brett, FM, Henson, C, Staunton, H.Familial diffuse Lewy body disease, eye movement abnorm alities, and distribution of pathology. Arch Neurol 2002; 59:464467.
137.St Clair, D, Norrman, J, Perry, R, et al. Apolipoprotein E epsilon 4allele frequency in patients with Lewy body dementia, Alzheimer’s disease and age-matched controls. Neurosci Lett 1994; 176:4546.
138.Benjamin, RLeake, A, Ince, PG, et al. Effects of apolipoprotein Egenotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer’s disease. Neurodegeneration 1995; 4:443448.
139.Martinoli, MG, Trojanowski, JQ, Schmidt, ML, et al. Association ofapolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol (Berl) 1995; 90:239243.
140.Hardy, J.Lewy bodies in Alzheimer’s disease in which the primarylesion is a mutation in the amyloid precursor protein. Neurosci Lett 1994; 180:290291.
141.Singleton, AB, Gibson, AM, McKeith, IG, et al. Alpha2-macroglobulin polymorphisms in Alzheimer’s disease and dementia with Lewy bodies. Neuroreport 1999; 10:15071510.
142.Singleton, AB, Lamb, H, Leake, A, et al. No association between apolymorphism in the presenilin 1 gene and dementia with Lewybodies. Neuroreport 1997; 8:36373639.
143.Lamb, H, Christie, J, Singleton, AB, et al. Apolipoprotein E andalpha-1 antichymotrypsin polymorphism genotyping in Alzheimer’s disease and in dementia with Lewy bodies. Distinctions between diseases. Neurology 1998; 50:388391.
144.Tanaka, S, Chen, X, Xia, Y, et al. Association of CYP2Dmicrosatellite polymorphism with Lewy body variant of Alzheimer’s disease. Neurology 1998; 50:15561562.
145.Atkinson, A, Singleton, AB, Steward, A, et al. CYP2D6 is associatedwith Parkinson’s disease but not with dementia with Lewy bodies or Alzheimer’s disease. Pharmacogenetics 1999; 9:3135.
146.Payami, H, Lee, N, Zareparsi, S, et al. Parkinson’s disease, CYP2D6polymorphism, and age. Neurology 2001; 56:13631370.
147.Chinnery, PF, Taylor, GA, Howell, N, et al. Mitochondrial DNAhaplogroups and susceptibility to AD and dementia with Lewybodies. Neurology 2000; 55:302304.
148.Takehashi, M, Tanaka, S, Masliah, E, Ueda, K.Association ofmonoamine oxidase A gene polymorphism with Alzheimer’s disease and Lewy body variant. Neurosci Lett 2002; 327:7982.
149.Farrer, M, Skipper, L, Berg, M, et al. The tau H1 haplotype isassociated with Parkinson’s disease in the Norwegian population. Neurosci Lett 2002; 322:8386.
150.Martin, ER, Scott, WK, Nance, MA, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001; 286:22452250.
151.de Silva, R, Hardy, J, Crook, J, et al. The tau locus is not significantlyassociated with pathologically confirmed sporadic Parkinson’sdisease. Neurosci Lett 2002; 330:201203.
152.Spillantini, MG, Goedert, M.Tau and Parkinson disease. JAMA 2001; 286:23242326.
153.Scott, WK, Nance, MA, Watts, RL, et al. Complete genomic screenin Parkinson disease: evidence for multiple genes. JAMA 2001; 286:22392244.
154.Gwinn-Hardy, K, Mehta, ND, Farrer, M, et al. Distinctiveneuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (Berl) 2000; 99:663672.
155.Gwinn-Hardy, K.Genetics of parkinsonism. Mov Disord 2002; 17:645656.
156.Dujardin, K, Duhamel, A, Becquet, E, et al. Neuropsychologicalabnormalities in first degree relatives of patients with familial Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:323328.
157.Montgomery, EB Jr, Baker, KB, Lyons, K, Koller, WC.Abnormalperformance on the PD test battery by asymptomatic first-degreerelatives. Neurology 1999; 52:757762.
158.Richard, IH, Papka, M, Rubio, A, Kurlan, R. Parkinson’s disease anddementia with Lewy bodies: one disease or two? Mov Disord 2002; 17:11611165.
159.Verghese, J, Crystal, HA, Dickson, DW, Lipton, RB.Validity ofclinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999; 53:19741982.
160.Hohl, U, Tiraboschi, P, Hansen, LA, Thal, LJ, Corey-Bloom, J.Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol 2000; 57:347351.
161.Lopez, OL, Becker, JT, Kaufer, DI, et al. Research evaluation andprospective diagnosis of dementia with Lewy bodies. ArchNeurol 2002; 59:4346.
162.Aarsland, D, Cummings, JL,Larsen, JP.Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’sdisease. Int J Geriatr Psychiatry 2001; 16:184191.
163.Aarsland, D, Ballard, C, Larsen, JP, McKeith, I.A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J GeriatrPsychiatry 2001; 16:528536.
164.Apaydin, H, Ahlskog, JE, Parisi, JE, Boeve, BF, Dickson, DW.Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59:102112.
165.Hurtig , HI, Trojanowski, JQ, Galvin, J, et al. Alpha-synuclein corticalLewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000; 54:19161921.
166.Goetz, CG, Vogel, C, Tanner, CM, Stebbins, GT.Early dopaminergicdrug-induced hallucinations in parkinsonian patients. Neurology 1998; 51:811814.
167.McKeith, IG.Dementia with Lewy bodies. Br J Psychiatry 2002; 180:144147.
168.Perry, E, Court, J, Goodchild, R, et al. Clinical neurochemistry:developments in dementia research based on brain bank material. J Neural Transm 1998; 105:915933.
169.Harding, AJ, Stimson, E, Henderson, JM, Halliday, GM.Clinicalcorrelates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 2002; 125:24312445.
170.Boeve, BF, Silber, MH, Ferman, TJ, Lucas, JA, Parisi, JE.Associationof REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16:622630.
171.Arnulf, I, Bonnet, AM, Damier, P, et al. Hallucinations, REM sleep,and Parkinson’s disease: a medical hypothesis. Neurology 2000; 55:281288.
172.Aarsland, D, Ballard, C, McKeith, I, Perry, RH, Larsen, JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13:374379.
173.Braak, H, Tredici, KD, Rub, U, et al. Staging of brain pathologyrelated to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24:197211.
174.Jellinger, KA, Seppi, K, Wenning, GK, Poewe, W.Impact ofcoexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 2002; 109:329339.
175.Mattila, PM, Rinne, JO, Helenius, H, Dickson, DW, Roytta, M.Alpha-synuclein-immunoreactive cortical Lewy bodies are associated withcognitiveimpairment inParkinson’s disease. Act a Neuropathol (Berl) 2000; 100:285290.
176.Mattila, PM, Roytta, M, Torikka, H, Dickson, DW, Rinne, JO.CorticalLewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. Acta Neuropathol (Berl) 1998; 95:576582.
177.de Vos, RA, Jansen, EN, Stam, FC, Ravid, R, Swaab, DF.’Lewy bodydisease’: clinico-pathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia. Clin Neurol Neurosurg 1995; 97:1322.
178.Churchyard, A, Lees, AJ.The relationship between dementia anddirect involvement of the hippocampus and amygdala in Parkinson’s disease. Neurology 1997; 49:15701576.
179.Gomez-Tortosa, E, Newell, K, Irizarry, MC, et al. Clinical andquantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999; 53:12841291.
180.Masliah, E, Rockenstein, E, Veinbergs, I, et al. Beta-amyloid peptidesenhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 2001; 98:1224512250.
181.Hornykiewicz, O.Dopamine miracle: from brain homogenate todopamine replacement. Mov Disord 2002; 17:501508.
182.Hornykiewicz, O, Kish, SJ.Neurochemical basis of dementia inParkinson’s disease. Can J Neurol Sci 1984; 11:185190.
183.Chan-Palay, V, Asan, E.Alterations in catecholamine neurons of thelocus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989; 287:373392.
184.D’Amato, RJ, Zweig, RM, Whitehouse, PJ, et al. Aminergic systemsin Alzheimer’s disease and Parkinson’s disease. Ann Neurol 1987; 22:229236.
185.Mattila, PM, Roytta, M, Lonnberg, P, et al. Choline acety transfer as eactivity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol (Berl) 2001; 102:160166.
186.Tiraboschi, P, Hansen, LA, Alford, M, et al. Early and widespreadcholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002; 59:946951.
187.Court, JA, Piggott, MA, Lloyd, S, et al. Nicotine binding in humanstriatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 2000; 98:7987.
188.Perry, EK, Marshall, E, Thompson, P, et al. Monoaminergic activitiesin Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect 1993; 6:167177.
189.Joyce, JN, Ryoo, H, Gurevich, EV, Adler, C, Beach, T.Ventral striatalD(3) receptors and Parkinson’s disease. Parkinsonism Relat Disord 2001; 7:225230.
190.Piggott, MA, Marshall, EF, Thomas, N, et al. Striatal dopaminergicmarkers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 1999; 122 (Pt 8):14491468.
191.Joyce, JN, Ryoo, HL, Beach, TB, et al. Loss of response to levodopain Parkinson’s disease and co-occurrence with dementia: role ofD(3) and not D(2) receptors. Brain Res 2002; 955:138152.
192.Ito, K, Nagano-Saito, A, Kato, T, et al. Striatal and extra striataldys function in Parkinson’s disease with dementia: a 6-[18F]fluoro-L-dopa PETstudy. Brain 2002; 125:13581365.
193.Walker, Z, Costa, DC, Walker, RW, et al. Differentiation of dementiawith Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73:134140.
194.Ransmayrl, G, Seppi, K, Donnemiller, E, et al. Striatal dopaminetransporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 2001; 28:15231528.
195.Jagust, WJ, Reed, BR, Martin, EM, Eberling, JL, Nelson-Abbott, RA. Cognitive function and regional cerebral blood flow in Parkinson’s disease. Brain 1992; 115 (Pt 2):521537.
196.Wu, JC, Iacono, R, Ayman, M, et al. Correlation of intellectualimpairment in Parkinson’s disease with FDG PET scan. Neuroreport 2000; 11:21392144.
197.Wang, SJ, Liu, RS, Liu, HC, et al. Technetium-99mhexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson’s disease: correlation with dementia and lateralization. Eur J Nucl Med 1993; 20:339344.
198.Peppard, RF, Martin, WR, Carr, GD, et al. Cerebral glucosemetabolism in Parkinson’s disease with and without dementia. Arch Neurol 1992; 49:12621268.
199.Liu, RS, Lin, KN, Wang, SJ, et al. Cognition and 99Tcm-HMPAOSPECT in Parkinson’s disease. Nucl Med Commun 1992; 13:744748.
200.Sawada, H, Udaka, F, Kameyama, M, et al. SPECT findings inParkinson’s diseaseassociated with dementia. J NeurolNeurosurg Psychiatry 1992; 55:960963.
201.Spampinato, U, Habert, MO, Mas, JL, et al. (99mTc)-HM-PAOSPECT and cognitive impairment in Parkinson’s disease: a comparison with dementia of the Alzheimer type. J NeurolNeurosurg Psychiatry 1991; 54:787792.
202.Turjanski, N, Brooks, DJ.PET and the investigation of dementia inthe parkinsonian patient. J Neural Transm Suppl 1997; 51:3748.
203.Tachibana, H, Kawabata, K, Tomino, Y, Sugita, M, Fukuchi, M.Brain perfusion imaging in Parkinson’s disease and Alzheim er’s disease demonstrated by three-dimensional surface display with 123I-iodoamphetamine. Dementia 1993; 4:334341.
204.Antonini, A, De Notaris, R, Benti, R, De Gaspari, D, Pezzoli, G.Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson’s disease. Neurol Sci 2001; 22:4546.
205.Goto, I, Taniwaki, T, Hosokawa, S, et al. Positron emissiontomographic (PET) studies in dementia. J Neurol Sci 1993; 114:16.
206.Vander Borght, T, Minoshima, S, Giordani, B, et al. Cerebralmetabolic differences in Parkinson’s and Alzheimer’s diseasesmatched for dementia severity. J Nucl Med 1997; 38:797802.
207.Imamura, T, Ishii, K, Hirono, N, et al. Occipital glucose metabolismin dementia with lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr CognDisord 2001; 12:194197.
208.Kuhl, DE, Minoshima, S, Fessler, JA, et al. In vivo mapping ofcholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996; 40:399410.
209.Defebvre, LJ, Leduc, V, Duhamel, A, et al. Technetium HMPAOSPECTstudy in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J Nucl Med 1999; 40:956962.
210.Donnemiller, E, Heilmann, J, Wenning, GK, et al. Brain perfusionscintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24:320325.
211.Lobotesis, K, Fenwick, JD, Phipps, A, et al. Occipital hypoperfusionon SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56:643649.
212.Ishii, K, Yamaji, S, Kitagaki, H, et al. Regional cerebral blood flowd i fference between dementia with Lewy bodies and AD. Neurology 1999; 53:413416.
213.Colloby, SJ, Fenwick, JD, Williams, ED, et al. A comparison of(99m) Tc-HMPAOSPECT changes in dementia with Lewybodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002; 29:615622.
214.Varma, AR, Talbot, PR, Snowden, JS, et al. A 99mTc-HMPAOsingle-photon emission computed tomography study of Lewy bodydisease. J Neurol 1997; 244:349359.
215.Alegret, M, Junque, C, Pueyo, R, et al. MRI atrophy parametersrelated to cognitive and motor impairment in Parkinson’s disease. Neurologia 2001; 16:6369.
216.Hu, MT, White, SJ, Chaudhuri, KR, et al. Correlating rates of cerebralatrophy in Parkinson’s disease with measures of cognitive decline. J Neural Transm 2001; 108:571580.
217.Laakso, MP, Partanen, K, Riekkinen, P, et al. Hippocampal volumesin Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996; 46:678681.
218.Cordato, NJ, Pantelis, C, Halliday, GM, et al. Frontal atrophycorrelates with behavioural changes in progressive supranuclearpalsy. Brain 2002; 125:789800.
219.Camicioli, R, Moore, M, Kinney, A, et al. Parkinson’s disease is asso-ciated with hippocampal atrophy. Mov Disord 2003;18:784790.
220.Hashimoto, M, Kitagaki, H, Imamura, T, et al. Medial temporal andwhole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology 1998; 51:357362.
221.Harvey, GT, Hughes, J, McKeith, IG, et al. Magnetic resonanceimaging differences between dementia with Lewy bodies and Alzheimer’s disease: a pilot study. Psychol Med 1999; 29:181187.
222.Barber, R, Ballard, C, McKeith, IG, Gholkar, A, O’Brien, JT.MRIvolumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54:13041309.
223.Barber, R, McKeith, IG, Ballard, C, Gholkar, A, O’Brien, JT.Acomparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer’s disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 2001; 12:198205.
224.Hanyu, H, Asano, T, Sakurai, H, et al. MR analysis of the substantiainnominata in normal aging, Alzheimer disease, and other typesof dementia. AJNR Am J Neuroradiol 2002; 23:2732.
225.O’Brien, JT, Paling, S, Barber, R, et al. Progressive brain atrophy onserial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001; 56:13861388.
226.Barber, R, McKeith, I, Ballard, C, O’Brien, J.Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. J Neurol Neurosurg Psychiatry 2002; 72:406407.
227.Middelkoop, HA, van der Flier, WM, Burton, EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001; 57:21172120.
228.Barber , R, Scheltens, P, Gholkar, A, et al. White matter lesions onmagnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999; 67:6672.
229.Hu, MT, Taylor-Robinson, SD, Chaudhuri, KR, et al. Evidence forcortical dysfunction in clinically non-demented patients with Parkinson’s disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999; 67:2026.
230.Molina, JA, Garcia-Segura, JM, Benito-Leon, J, et al. Protonmagnetic resonance spectroscopy in dementia with Lewy bodies. Eur Neurol 2002; 48:158163.
231. Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magneticresonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch Neurol 2002; 59:835-842.
232.Saint-Cyr, JA, Trepanier, LL.Neuropsychologic assessment ofpatients for movement disorder surgery. Mov Disord 2000; 15:771783.
233.Jahanshahi, M, Ardouin, CM,Brown, RG, et al. The impact of deepbrain stimulation on executive function in Parkinson’s disease. Brain 2000; 123 (Pt 6):11421154.
234.Patterson, C, Gauthier, S, Bergman, H, et al. The recognition,assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci 2001; 28 (Suppl 1):S3-S16.
235.Chertkow, H, Bergman, H, Schipper, HM, et al. Assessment of suspected dementia. Can J Neurol Sci 2001; 28 (Suppl 1):S28-41.
236.Hogan, DB, Jennett, P, Freter, S, et al. Recommendations of theCanadian Consensus Conference on Dementia--dissemination, implementation, and evaluation of impact. Can J Neurol Sci 2001; 28 (Suppl 1):S115-S121.
237.Shulman, LM, Singer, C, Levin, B, Weiner, WJ.Diagnostic testing fordementia in patients with Parkinson’s disease. J Am Geriatr Soc 1996; 44:214215.
238.Hejl, A, Hogh, P, Waldemar, G.Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002; 73:390394.
239.Bayles, KA, Tomoeda, CK, Wood, JA, et al. Change in cognitivefunction in idiopathic Parkinson disease. Arch Neurol 1996; 53:11401146.
240.Jefferson, AL, Cosentino, SA, Ball, SK, et al. Errors produced on themini-mental state examination and neuropsychological test performance in Alzheimer’s disease, ischemic vascular dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002; 14:311320.
241.Rothlind, JC, Brandt, J.A brief assessment of frontal and subcorticalfunctions in dementia. J Neuropsychiatry Clin Neurosci 1993; 5:7377.
242.Huber, SJ, Shuttleworth, EC, Christy, JA, Rice, RR.A brief scale forthe dementia of Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1990; 2:183188.
243.Cubo, E, Bernard, B, Leurgans, S, Raman, R.Cognitive and motorfunction in patients with Parkinson’s disease with and without depression. Clin Neuropharmacol 2000; 23:331334.
244.Norman, S, Troster, AI, Fields, JA, Brooks, R.Effects of depressionand Parkinson’s disease on cognitive functioning. J Neuropsychiatry Clin Neurosci 2002; 14:3136.
245.Beck, AT, Steer, RA, Brown, GK.BDI-II, Beck DepressionInventory: Manual. San Antonio, Texas: Psychological Corp. Harcourt Brace, 1996.
246.Hamilton, M.Development of a rating scale for primary depressiveillness. Br J Soc Clin Psychol 1967; 6:278296.
247.Yesavage, JA.Geriatric Depression Scale. Psychopharmacol Bull 1988; 24:709711.
248.Alexopoulos, GS, Abrams, RC, Young, RC, Shamoian, CA.CornellScale for Depression in Dementia. Biol Psychiatry 1988; 23:271284.
249.de Smet, Y, Ruberg, M, Serdaru, M, et al. Confusion, dementia andanticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1982; 45:11611164.
250.Cooper, JA, Sagar, HJ, Doherty, SM, et al. Different effects ofdopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 1992; 115 (Pt 6):17011725.
251.Dubois, B, Pilon, B, Lhermitte, F, Agid, Y.Cholinergic deficiency andfrontal dysfunction in Parkinson’s disease. Ann Neurol 1990; 28:117121.
252.Pondal, M, Del Ser, T, Bermejo, F.Anticholinergic therapy anddementia in patients with Parkinson’s disease. J Neurol 1996; 243:543546.
253.Bedard , MA, Pillon, B, Dubois, B, et al. Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40:289313.
254.Miyasaki, JM, Grimes, D, Lang, AE.Acute delirium after withdrawalof amantadine in Parkinson’s disease. Neurology 1999; 52:17201721.
255.Factor, SA, Molho, ES, Brown, DL.Acute delirium after withdrawal ofamantadine in Parkinson’s disease. Neurology 1998; 50:14561458.
256.Reimer, J, Kuhlmann, A, Muller, T.Neuroleptic malignant-likesyndrome after rapid switch from bromocriptine to pergolide. Parkinsonism Relat Disord 2002; 9:115116.
257.Ueda, M, Hamamoto, M, Nagayama, H, et al. Biochemical alterationsduring medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001; 71:111113.
258.Reutens, DC, Harrison, WB, Goldswain, PR.Neuroleptic malignantsyndrome complicating levodopa withdrawal. Med J Aust 1991; 155:5354.
259.Weller, M, Kornhuber, J.Amantadine withdrawal and neurolepticmalignant syndrome. Neurology 1993; 43:2155.
260.Friedman, JH, Fernandez, HH.A typical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 2002; 15:156170.
261.Tarsy, D, Baldessarini, RJ, Tarazi, FI.Effects of newer antipsychoticson extrapyramidal function. CNS Drugs 2002; 16:2345.
262.The Parkinson Study Group. Low-dose clozapine for the treatmentof drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999; 340:757763.
263.Goetz, CG, Blasucci, LM, Leurgans, S, Pappert, EJ.Olanzapine andclozapine: comparative effects on motor function in hallucinatingPD patients. Neurology 2000; 55:789794.
264.Ondo, WG, Levy, JK, Vuong, KD, Hunter, C, Jankovic, J.Olanzapinetreatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17:10311035.
265.Gimenez-Roldan, S, Mateo, D, Navarro, E, Gines, MM.Efficacy andsafety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson’s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001; 7:121127.
266.Walker, Z, Costa, DC, Ince, P, McKeith, IG, Katona, CL.In-vivodemonstration of dopaminergic degeneration in dementia withLewy bodies. Lancet 1999; 354:646647.
267.Reddy, S, Factor, SA, Molho, ES, Feustel, PJ.The effect of quetiapineon psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17:676681.
268.Fernandez, HH, Trieschmann, ME, Burke, MA, Friedman, JH.Quetiapine for psychosis in Parkinson’s disease versus dementiawith Lewy bodies. J Clin Psychiatry 2002; 63:513515.
269.Seeman, P.A typical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:2738.
270.Duvoisin, RC.Cholinerg ic-anticholinergic antagonism inparkinsonism. Arch Neurol 1967; 17:124136.
271.Richard, IH, Justus, AW, Greig, NH, Marshall, F, Kurlan, R.Worsening of motor function and mood in a patient with Parkinson’s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002; 25:296299.
272.McKeith, I, Del Ser, T, Spano, P, et al. Efficacy of rivastigmine indementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:20312036.
273.Reading , PJ, Luce, AK, McKeith, IG.Rivastigmine in the treatmentof parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16:11711174.
274.Bullock, R, Cameron, A.Rivastigmine for the treatment of dementiaand visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002; 18:258264.
275.Fabbrini, G, Barbanti, P, Aurilia, C, et al. Donepezil in the treatmentof hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23:4143.
276.Bergman, J, Lerner, V.Successful use of donepezil for the treatmentof psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25:107110.
277.Aarsland, D, Laake, K, Larsen, JP, Janvin, C.Donepezil for cognitiveimpairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708712.
278.Werber, EA, Rabey, JM.The beneficial effect of cholinesteraseinhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm 2001; 108:13191325.
279.Hutchinson, M, Fazzini, E.Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61:324325.
280.Kelton, MC, Kahn, HJ, Conrath, CL, Newhouse, PA.The effects ofnicotine on Parkinson’s disease. Brain Cogn 2000; 43:274282.
281.Jann, MW, Shirley, KL, Small, GW.Clinical pharmacokinetics andpharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41:719739.
282.Santos, MD, Alkondon, M, Pereira, EF, et al. The nicotinic allostericpotentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61:12221234.

Related content

Powered by UNSILO